135 related articles for article (PubMed ID: 37970726)
1. Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?".
Zubiaur P; Leeder JS; Abad-Santos F; Gaedigk A
Clin Pharmacol Ther; 2024 Feb; 115(2):184. PubMed ID: 37970726
[No Abstract] [Full Text] [Related]
2. Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children.
Kyler KE; Gaedigk A; Abdel-Rahman S; Staggs VS; Pearce RE; Toren P; Leeder JS; Shakhnovich V
Clin Transl Sci; 2024 Apr; 17(4):e13782. PubMed ID: 38629502
[TBL] [Abstract][Full Text] [Related]
3. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.
Suarez-Kurtz G; Genro JP; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Ribeiro-dos-Santos A; Romano-Silva MA; Santana I; Struchiner CJ
Pharmacogenomics J; 2012 Jun; 12(3):267-76. PubMed ID: 21173785
[TBL] [Abstract][Full Text] [Related]
4. Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population.
Pedersen RS; Christensen MM; Brøsen K
Eur J Clin Pharmacol; 2012 Oct; 68(10):1463-4. PubMed ID: 22476388
[No Abstract] [Full Text] [Related]
5. A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram.
Bråten LS; Haslemo T; Jukic MM; Ivanov M; Ingelman-Sundberg M; Molden E; Kringen MK
Clin Pharmacol Ther; 2021 Sep; 110(3):786-793. PubMed ID: 33759177
[TBL] [Abstract][Full Text] [Related]
6. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.
Pimenoff VN; Laval G; Comas D; Palo JU; Gut I; Cann H; Excoffier L; Sajantila A
Pharmacogenet Genomics; 2012 Dec; 22(12):846-57. PubMed ID: 23089684
[TBL] [Abstract][Full Text] [Related]
7. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.
Pedersen RS; Brasch-Andersen C; Sim SC; Bergmann TK; Halling J; Petersen MS; Weihe P; Edvardsen H; Kristensen VN; Brøsen K; Ingelman-Sundberg M
Eur J Clin Pharmacol; 2010 Dec; 66(12):1199-205. PubMed ID: 20665013
[TBL] [Abstract][Full Text] [Related]
8. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.
Martis S; Peter I; Hulot JS; Kornreich R; Desnick RJ; Scott SA
Pharmacogenomics J; 2013 Aug; 13(4):369-77. PubMed ID: 22491019
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population.
Flachsbart F; Ufer M; Kleindorp R; Nikolaus S; Schreiber S; Nebel A
J Gerontol A Biol Sci Med Sci; 2011 Nov; 66(11):1186-91. PubMed ID: 21798861
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines.
Scheer N; Kapelyukh Y; Chatham L; Rode A; Buechel S; Wolf CR
Mol Pharmacol; 2012 Dec; 82(6):1022-9. PubMed ID: 22918969
[TBL] [Abstract][Full Text] [Related]
11. Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population.
Bråten LS; Ingelman-Sundberg M; Jukic MM; Molden E; Kringen MK
Clin Transl Sci; 2022 Sep; 15(9):2135-2145. PubMed ID: 35668575
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of some genetic polymorphisms of cytochrome P-450: family CYP1 and subfamilies CYP2A, CYP2B and CYP2C].
Wojtczak A; Skretkowicz J
Pol Merkur Lekarski; 2009 Mar; 26(153):248-52. PubMed ID: 19388543
[TBL] [Abstract][Full Text] [Related]
13. CYP2C and CYP2B Mediated Metabolic Activation of Retrorsine in Cyp3a Knockout Mice.
Pang X; Tang C; Kong F; Chen M; Chen X
Curr Drug Metab; 2020; 21(13):1040-1051. PubMed ID: 33267758
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of CYP2C subfamily in a Japanese population.
Ieiri I; Higuchi S
J Toxicol Sci; 1998 Jul; 23 Suppl 2():129-31. PubMed ID: 9760448
[No Abstract] [Full Text] [Related]
15. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.
Miners JO; Coulter S; Birkett DJ; Goldstein JA
Pharmacogenetics; 2000 Apr; 10(3):267-70. PubMed ID: 10803683
[No Abstract] [Full Text] [Related]
16. Genetic variation at the CYP2C locus and its association with torsemide biotransformation.
Vormfelde SV; Schirmer M; Toliat MR; Meineke I; Kirchheiner J; Nürnberg P; Brockmöller J
Pharmacogenomics J; 2007 Jun; 7(3):200-11. PubMed ID: 16969365
[TBL] [Abstract][Full Text] [Related]
17. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.
Scott SA; Sangkuhl K; Shuldiner AR; Hulot JS; Thorn CF; Altman RB; Klein TE
Pharmacogenet Genomics; 2012 Feb; 22(2):159-65. PubMed ID: 22027650
[TBL] [Abstract][Full Text] [Related]
18. Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor.
Martínez C; García-Martín E; Alonso-Navarro H; Jiménez-Jiménez FJ; Benito-León J; García-Ferrer I; Vázquez-Torres P; Puertas I; Zurdo JM; López-Alburquerque T; Agúndez JA
Neuromolecular Med; 2007; 9(2):195-204. PubMed ID: 17627038
[TBL] [Abstract][Full Text] [Related]
19. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily.
Lewis DF; Dickins M; Weaver RJ; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1998 Mar; 28(3):235-68. PubMed ID: 9574814
[TBL] [Abstract][Full Text] [Related]
20. Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10.
Walton R; Kimber M; Rockett K; Trafford C; Kwiatkowski D; Sirugo G
Nat Genet; 2005 Sep; 37(9):915-6; author reply 916. PubMed ID: 16132042
[No Abstract] [Full Text] [Related]
[Next] [New Search]
